MicroRNA-21: From Cancer to Cardiovascular Disease
Abstract
MicroRNA-21 (miR-21) expression is activated in multiple types of cancers, such as breast, liver, brain, prostate, myometrial cancers but also in cardiovascular diseases. MiR-21 regulates a plethora of target proteins which are involved in cellular survival, apoptosis and cell invasiveness. MiR-21 regulation is complex due to an own promoter that is target for various transcription factors and hormones. The consistent miR-21 overexpression under pathophysiological conditions points to miR-21 as a valuable tool for new therapeutic strategies. In this review, we present and analyze current data about miR-21 expression in various pathologies ranging from cancer to cardiovascular disease. Further, miR-21 regulatory mechanisms and miR-21 downstream targets are discussed. Finally, we highlight the particular role of miR-21 as a therapeutic target in various diseases.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is ample evidence that miR-21 expression really is altered in many disease states.
“One important point about all of these studies is that there is ample evidence that miR-21 expression really is altered in many disease states [11, 20, 77, 78].”
From miR-21: a non‐specific biomarker of all maladies (2021) · cites this paper as [78]
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
Cited by 226
- Authors
- Jazbutyte, V., & Thum, T.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Thum, Thomas
- ORCID
- Thum, Thomas
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-08-01
- Volume
- 11
- Issue
- 8
- Pages
- 926-935
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2085749269
- Cited by
- 226
- References
- 0
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 4 · 2023: 4 · 2022: 3 · 2021: 14 · 2020: 11 · 2019: 9 · 2018: 13 · 2017: 18 · 2016: 20 · 2015: 23 · 2014: 23 · 2013: 25 · 2012: 19
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Plant Molecular Biology Research
- Keywords
- miR-21, cancer, cardiovascular disease, transcription factors, hormonal regulation, apoptosis, cell invasion, therapeutic target
- MeSH terms
- Animals, Cardiovascular Diseases, Cell Survival, Gene Expression Regulation, Humans, Neoplasms, Drug Delivery Systems, MicroRNAs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
